Evidence map›Paper›PMID 31874623›Full record

ArticleBMC bioinformatics2019

Drug repositioning based on individual bi-random walks on a heterogeneous network.

Yuehui Wang, Maozu Guo, Yazhou Ren, Lianyin Jia, Guoxian Yu

Open access · goldAbstract read
In one paragraph

Article in BMC bioinformatics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Yuehui WangCollege of Computer and Information Sciences, Southwest University, Beibei, Chongqing, 400715, China.
Maozu GuoSchool of Electrical and Information Engineering, Beijing University of Civil Engineering and Architecture, Beijing, 100044, China. guomaozu@bucea.edu.cn.
Yazhou RenSchool of Computer Science and Engineering, University of Electronic Science and Technology of China, Chengdu, 611731, China.
Lianyin JiaCollege of Information Engineering and Automation, Kunming University of Science and Technology, Kunming, 650504, China.
Guoxian YuCollege of Computer and Information Sciences, Southwest University, Beibei, Chongqing, 400715, China. gxyu@swu.edu.cn.ORCID http://orcid.org/0000-0002-1667-6705
Southwest University · CNBeijing University of Civil Engineering and Architecture · CNKunming University of Science and Technology · CNUniversity of Electronic Science and Technology of China · CN

Funding

Fundamental Research Funds for the Central Universities XDJK2019B024Natural Science Foundation of China 61741214Natural Science Foundation of China 61872300Natural Science Foundation Project of Chongqing, Chongqing Science and Technology Commission cstc2018jcyjAX0228
6 · The paper itself

Abstract

backgroundTraditional drug research and development is high cost, time-consuming and risky. Computationally identifying new indications for existing drugs, referred as drug repositioning, greatly reduces the cost and attracts ever-increasing research interests. Many network-based methods have been proposed for drug repositioning and most of them apply random walk on a heterogeneous network consisted with disease and drug nodes. However, these methods generally adopt the same walk-length for all nodes, and ignore the different contributions of different nodes.

resultsIn this study, we propose a drug repositioning approach based on individual bi-random walks (DR-IBRW) on the heterogeneous network. DR-IBRW firstly quantifies the individual work-length of random walks for each node based on the network topology and knowledge that similar drugs tend to be associated with similar diseases. To account for the inner structural difference of the heterogeneous network, it performs bi-random walks with the quantified walk-lengths, and thus to identify new indications for approved drugs. Empirical study on public datasets shows that DR-IBRW achieves a much better drug repositioning performance than other related competitive methods.

conclusionsUsing individual random walk-lengths for different nodes of heterogeneous network indeed boosts the repositioning performance. DR-IBRW can be easily generalized to prioritize links between nodes of a network.

Indexed as

Drug RepositioningComputational BiologyDrug ApprovalBi-random walksDrug-disease heterogeneous networkDrug repositioningIndividual walk-length

Identifiers

PMID31874623
PMCPMC6929332
OpenAlexW2997833976

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.